Baidu
map

Cell Reports:肿瘤干细胞调节的新研究

2015-02-10 MedSci MedSci原创

桑福德伯翰医学研究所的研究人员发现了一个精确的干细胞信号转导过程,如果该信号通路中断则会导致肠道肿瘤。这些发现有助于我们对如何干细胞如何引起肿瘤以及识别特定的干细胞的分子的理解,这可以有针对性的预防肠道癌症肿瘤发生,进展以及癌症复发。今天这项研究的结果在线发表在Cell  Report。 桑福德伯翰的细胞死亡和生存网络项目主管Jorge Moscat博士说:“越来越多的证据表明,肿瘤干

桑福德伯翰医学研究所的研究人员发现了一个精确的干细胞信号转导过程,如果该信号通路中断则会导致肠道肿瘤。这些发现有助于我们对如何干细胞如何引起肿瘤以及识别特定的干细胞的分子的理解,这可以有针对性的预防肠道癌症肿瘤发生,进展以及癌症复发。今天这项研究的结果在线发表在Cell  Report。

桑福德伯翰的细胞死亡和生存网络项目主管Jorge Moscat博士说:“越来越多的证据表明,肿瘤干细胞是负责肿瘤的发生,发展,转移,复发以及耐药性的。我们新的研究成果可以为信号级联调节干细胞提供更好地理解,并且对设计新的和更有效的治疗癌症的方法也是非常重要的,”
     
该项目的教授,也是本文章的第二作者Maria教授说:“我们已经表明,蛋白激酶C-ζ(PKCζ)通常通过下调两个信号通路来抑制干细胞的活性:β-catenin and Yap。我们的实验室以前的研究结果表明,PKC-ζ作为一个肿瘤抑制因子来维持肠干细胞的动态平衡。目前的研究揭示了通过其发生的机制。”
     
覆盖肠道的单层上皮细胞每3-5天更新一次。那些取代了这些上皮细胞的细胞—肠道干细胞,需要进行调节来保持动态平衡。
     
迪亚兹—梅科说: “令人不安的是,干细胞池的动态平衡可以通过两种方式 : 它可以减少肠道上皮细胞的再生或增加干细胞的增殖,癌症是由控制细胞生长的中枢机制的关键基因的突变积累产生的。干细胞在肠道中是一个‘永久性’的角色,并且是那些突变细胞的储藏库。因此,如果干细胞活性增强,如在PKC-ζ电肠子缺失的情况下,然后显影肿瘤的可能性要高得多,并且将在启动肿瘤后变得更具侵袭性。”
       
使用基因工程小鼠模肠癌模型,研究小组发现,这一过程被两个主要肿瘤启动因子:β-catenin和Yap被PKCζ直接磷酸化控制。
         
“重要的是,我们证实了PKCζ、β-catenin和Yap在人结肠腺癌样本的致瘤谱。人样本实验和小鼠体内模型结果的相关性研究表明YAP和β-catenin是PKCζ潜在的底物,这或许将成为一种新的抗癌疗法。
        
Moscat说:“我们的研究结果显示,通过阻断导致肿瘤的途径,可以为肠道癌症的预防和治疗提供了新的可能性。”他们还强调急性或慢性损伤后促进肠再生的新策略,如化疗和放疗引起的。

原始出处

Victoria Llado, Yuki Nakanishi, Angeles Duran, Miguel Reina-Campos, Phillip M. Shelton, Juan F. Linares, Tomoko Yajima, Alex Campos, Pedro Aza-Blanc, Michael Leitges, Maria T. Diaz-Meco, Jorge Moscat. Repression of Intestinal Stem Cell Function and Tumorigenesis through Direct Phosphorylation of β-Catenin and Yap by PKCζ. Cell Reports, 2015

本文是MedSci编译,欢迎转载,转载请注明出处,非常感谢!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=331567, encodeId=75b133156e4b, content=YAP和β-catenin是PKCζ潜在的底物.这或许将成为一种新的抗癌疗法., beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b6892045898, createdName=susanay, createdTime=Sat Jul 14 16:36:07 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869023, encodeId=1511186902364, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Aug 06 20:47:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959274, encodeId=d55119592e4ff, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Apr 22 13:47:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16595, encodeId=bb9e1659516, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:21:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15780, encodeId=148515e8039, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:04:00 CST 2015, time=2015-02-16, status=1, ipAttribution=)]
    2018-07-14 susanay

    YAP和β-catenin是PKCζ潜在的底物.这或许将成为一种新的抗癌疗法.

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=331567, encodeId=75b133156e4b, content=YAP和β-catenin是PKCζ潜在的底物.这或许将成为一种新的抗癌疗法., beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b6892045898, createdName=susanay, createdTime=Sat Jul 14 16:36:07 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869023, encodeId=1511186902364, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Aug 06 20:47:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959274, encodeId=d55119592e4ff, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Apr 22 13:47:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16595, encodeId=bb9e1659516, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:21:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15780, encodeId=148515e8039, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:04:00 CST 2015, time=2015-02-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=331567, encodeId=75b133156e4b, content=YAP和β-catenin是PKCζ潜在的底物.这或许将成为一种新的抗癌疗法., beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b6892045898, createdName=susanay, createdTime=Sat Jul 14 16:36:07 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869023, encodeId=1511186902364, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Aug 06 20:47:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959274, encodeId=d55119592e4ff, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Apr 22 13:47:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16595, encodeId=bb9e1659516, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:21:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15780, encodeId=148515e8039, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:04:00 CST 2015, time=2015-02-16, status=1, ipAttribution=)]
    2015-04-22 维他命
  4. [GetPortalCommentsPageByObjectIdResponse(id=331567, encodeId=75b133156e4b, content=YAP和β-catenin是PKCζ潜在的底物.这或许将成为一种新的抗癌疗法., beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b6892045898, createdName=susanay, createdTime=Sat Jul 14 16:36:07 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869023, encodeId=1511186902364, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Aug 06 20:47:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959274, encodeId=d55119592e4ff, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Apr 22 13:47:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16595, encodeId=bb9e1659516, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:21:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15780, encodeId=148515e8039, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:04:00 CST 2015, time=2015-02-16, status=1, ipAttribution=)]
    2015-02-20 orthoW

    很不错学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=331567, encodeId=75b133156e4b, content=YAP和β-catenin是PKCζ潜在的底物.这或许将成为一种新的抗癌疗法., beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b6892045898, createdName=susanay, createdTime=Sat Jul 14 16:36:07 CST 2018, time=2018-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869023, encodeId=1511186902364, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Thu Aug 06 20:47:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959274, encodeId=d55119592e4ff, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Wed Apr 22 13:47:00 CST 2015, time=2015-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16595, encodeId=bb9e1659516, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:21:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15780, encodeId=148515e8039, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:04:00 CST 2015, time=2015-02-16, status=1, ipAttribution=)]
    2015-02-16 windmilL1989

    以阅

    0

相关资讯

Nature Communications:监测肿瘤状态的特殊基因

近日,刊登在国际杂志Nature Communications上的一篇研究论文中,来自西奈山医疗中心(Mount Sinai Medical Center)的研究人员通过研究发现两种癌症药物可以开启特殊基因的表达,而这种特殊基因则可以告知肿瘤细胞使其处于休眠状态。 文章中研究者表示,当名为NR2F1的基因开启后其就会重编程肿瘤细胞使其处于休眠状态;而当该基因的表达关闭后肿瘤细胞就会开始分裂并且发

卫计委《肿瘤登记管理办法》解读

近日,国家卫生计生委和国家中医药管理局联合印发了《肿瘤登记管理办法》》(以下简称《管理办法》)。现对有关要点解读如下: 一、起草背景 肿瘤登记是系统性、经常性收集有关肿瘤及肿瘤病人信息的统计制度,是癌症防治工作的基础。为掌握我国癌症发病、死亡情况,2008年,中央财政支持开展肿瘤登记项目工作,项目覆盖面和覆盖人群不断扩大,到2014年全国肿瘤登记点已达308个,覆盖全国约3亿人。肿瘤登记项目工

Oncoimmunology:重新编码肿瘤保护巨噬细胞,召唤大批“卧底”

Norris Cotton肿瘤中心和达特茅斯Geisel医学院的研究人员发现将特定菌株插入恶性卵巢癌微环境中,肿瘤细胞行为发生转变,从抑制免疫反应变为激活免疫系统。该研究结果发表在OncoImmunology,证明了一种可在多种癌症类型应用的免疫治疗新方法。 这种特殊的菌株是一种弱化而又安全的细菌——李斯特菌( Listeria monocytogenes,Lm)。肿瘤细胞通过产生免疫抑制微环境

Stroke:可植入共振器监测肿瘤深处氧气含量

近日,一篇发表在国际杂志Stroke上的研究论文中,来自Norris Cotton综合癌症研究中心的研究人员通过研究开发了一种名为电子顺磁共振(EPR)血氧测定的新技术,该技术可帮助临床医生直接测定癌症及中风患者在高氧水平下的氧气含量,为规范疾病疗法有效改善患者的预后提供了一定的帮助。氧气对维持生命必不可少,细胞和组织中特定水平的氧气对于维持机体正常的功能非常重要,同时氧气在许多疾病的发生及疗法过

Nature:靶向肿瘤微环境,用antimiR治疗肿瘤

近日,著名国际期刊Nature发表了耶鲁大学研究人员的一项最新研究成果,他们建立了一个能够将antimiR靶向输送到酸性肿瘤微环境的药物输送平台,通过抑制miR-155表达,抑制淋巴癌发展。这一研究成果对靶向药物输送系统研究以及通过antimiR治疗癌症具有重要意义。   MicroRNA是是一类短的非编码RNA,表达在不同组织和不同细胞类型中,能够抑制靶标基因的表达。MicroRN

Nat Commun:阻断血管生成素的肿瘤治疗为何效果不一?

芬兰赫尔辛基大学(University of Helsinki)的科学家们最近表示他们或找到通过阻断肿瘤血管生成的肿瘤治疗有时候会失败的原因。这个观点发表在Nature Reviews Drug Discovery杂志,而相关的研究论文发表在Nature Communications上。 血管生成素阻断治疗是通过阻断肿瘤血管生长而杀死肿瘤细胞的一种疗法。这种治疗,目前广泛应用在卵巢癌等癌症的

Baidu
map
Baidu
map
Baidu
map